Its opportune to point out that the collaboration will seek to exploit the scalability of the platform. It isn't the case of developing one precision drug for one indication - there are 6000 rare genetic diseases. The decision to develop a platform specifically for antisense oligonucleotides has come after many twists, turns and cul-de-sacs. Phylogica is now, however, well placed to become a key player in the transformative and exciting future of precision medicine.
Its opportune to point out that the collaboration will seek to...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.24 |
Change
0.040(3.33%) |
Mkt cap ! $723.2M | |||
| Open | High | Low | Value | Volume |
| $1.20 | $1.24 | $1.19 | $1.500M | 1.241M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 204320 | $1.24 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.25 | 4333 | 2 |
View Market Depth
| Last trade - 16.11pm 24/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |